OBJECTIVES: This study evaluated the effects of antimicrobial treatment against vancomycin-resistant enterococci (VRE) and delayed administration of anti-VRE therapy on mortality, and determined independent risk factors for delayed all-cause mortality of VRE bacteremia patients. METHODS: Over 10 years, 153 patients with clinically significant monomicrobial VRE bacteremia were identified among a total of 2834 patients in a VRE cohort. The main outcomes were immediate (7-day) and delayed (28-day, 60-day) all-cause mortality. RESULTS: The 7-day (P<0.001) and 28-day (P=0.041) mortalities were lower in the group receiving anti-VRE therapy, but the 60-day mortality (P=0.113) was unaffected. The mortalities of patients receiving anti-VRE therapy later than 72h after the onset of bacteremia were no different from that of patients receiving treatment within 72h. Both a higher APACHE II score (hazard ratio [HR], 1.10; P<0.001 and HR, 1.12; P<0.001, respectively) and the presence of septic shock at the onset of bacteremia (HR, 1.91; P=0.047 and HR, 1.78; P=0.034, respectively) were independent risk factors for 28-day and 60-day mortality. CONCLUSION: These findings suggest that in spite of antibiotic therapy against VRE, patients with VRE bacteremia eventually have a higher risk of death because of severe illness at the onset of bacteremia.
OBJECTIVES: This study evaluated the effects of antimicrobial treatment against vancomycin-resistant enterococci (VRE) and delayed administration of anti-VRE therapy on mortality, and determined independent risk factors for delayed all-cause mortality of VRE bacteremiapatients. METHODS: Over 10 years, 153 patients with clinically significant monomicrobial VRE bacteremia were identified among a total of 2834 patients in a VRE cohort. The main outcomes were immediate (7-day) and delayed (28-day, 60-day) all-cause mortality. RESULTS: The 7-day (P<0.001) and 28-day (P=0.041) mortalities were lower in the group receiving anti-VRE therapy, but the 60-day mortality (P=0.113) was unaffected. The mortalities of patients receiving anti-VRE therapy later than 72h after the onset of bacteremia were no different from that of patients receiving treatment within 72h. Both a higher APACHE II score (hazard ratio [HR], 1.10; P<0.001 and HR, 1.12; P<0.001, respectively) and the presence of septic shock at the onset of bacteremia (HR, 1.91; P=0.047 and HR, 1.78; P=0.034, respectively) were independent risk factors for 28-day and 60-day mortality. CONCLUSION: These findings suggest that in spite of antibiotic therapy against VRE, patients with VRE bacteremia eventually have a higher risk of death because of severe illness at the onset of bacteremia.
Authors: Shawna Kraft; Emily Mackler; Peter Schlickman; Kathy Welch; Daryl D DePestel Journal: Support Care Cancer Date: 2010-11-26 Impact factor: 3.603
Authors: D Conde-Estévez; S Grau; J Albanell; R Terradas; M Salvadó; H Knobel Journal: Eur J Clin Microbiol Infect Dis Date: 2010-08-15 Impact factor: 3.267
Authors: Celestine S Tung; Charlotte C Sun; Matthew P Schlumbrecht; Larissa A Meyer; Diane C Bodurka Journal: Gynecol Oncol Date: 2009-09-18 Impact factor: 5.482
Authors: Evan J Zasowski; Kimberly C Claeys; Abdalhamid M Lagnf; Susan L Davis; Michael J Rybak Journal: Clin Infect Dis Date: 2016-03-03 Impact factor: 9.079
Authors: Michael A Pfaller; Martin Cormican; Robert K Flamm; Rodrigo E Mendes; Ronald N Jones Journal: Open Forum Infect Dis Date: 2019-03-15 Impact factor: 3.835